Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOTHEMACAS:SOT +1.07%67 Revenue per Share is MAD84.88 as of Dec. 2025. GuruFocus rates CAS:SOT with a GF Score™ of 67/100 and a GF Value™ of MAD290.87 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 905 Drug Manufacturers companies, SOTHEMA ranks better than 71.71% on this metric.
SOTHEMA's revenue per share for the
six
months ended in Dec. 2025 was MAD41.84.
SOTHEMA's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was MAD84.88.
Warning Sign:
SOTHEMA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of SOTHEMA was 8.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for SOTHEMA's Revenue per Share or its related term are showing as below:
CAS:SOT'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -29.8 Med: 10.15 Max: 71.9
Current: 9.9
During the past 13 years, SOTHEMA's highest 3-Year average Revenue Per Share Growth Rate was 71.90% per year. The lowest was -29.80% per year. And the median was 10.15% per year.
CAS:SOT's 3-Year Revenue Growth Rate is ranked better than 71.71% of 905
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs CAS:SOT: 9.90
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
SOTHEMA Revenue per Share Related Terms
SOTHEMA Revenue per Share Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: Revenue per Share Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's PS Ratio distribution charts can be found below:
* The bar in red indicates where SOTHEMA's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
SOTHEMA's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD84.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Revenue per Share of MAD84.88 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on SOTHEMA and its competitors. According to the industry distribution chart, SOTHEMA ranks #256 out of 905 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is SOTHEMA's Revenue per Share too high?
SOTHEMA's current Revenue per Share is MAD84.88. Based on the distribution chart, SOTHEMA ranks #256 out of 905 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SOTHEMA has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Revenue per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #256 out of 905 companies for Revenue per Share. This puts SOTHEMA in the upper half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current Revenue per Share is MAD84.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Modestly Overvalued. The stock's GF Value™ is MAD290.87, compared to a current price of MAD368.90 — trading 26.8% above its estimated fair value. The current Revenue per Share is MAD84.88. SOTHEMA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Revenue per Share is MAD84.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD368.90 is trading 26.8% above its estimated GF Value™ of MAD290.87.
GuruFocus considers SOTHEMA to be Modestly Overvalued.
Key valuation signals for CAS:SOT:
Revenue per Share: MAD84.88
GF Value™: MAD290.87 vs. price of MAD368.90 (26.8% above fair value)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
67GF Score
Get the complete analysis for CAS:SOT
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
